PMID- 19525846
OWN - NLM
STAT- MEDLINE
DCOM- 20091222
LR  - 20181201
IS  - 1473-5733 (Electronic)
IS  - 0957-5235 (Linking)
VI  - 20
IP  - 6
DP  - 2009 Sep
TI  - Effects of pitavastatin on monocyte chemoattractant protein-1 in hyperlipidemic 
      patients.
PG  - 440-7
LID - 10.1097/MBC.0b013e32832e0618 [doi]
AB  - The effects of statins on platelet activation markers, chemokines and 
      adiponectin, were investigated in 135 patients with hyperlipidemia. Of the 135 
      hyperlipidemic patients, 63 were allocated to the simvastatin group, treated with 
      simvastatin at the dose of 10 mg daily, and the remaining 72 were allocated to 
      the pitavastatin group, treated with pitavastatin at the dose of 2 mg daily. 
      Plasma levels of platelet-derived microparticles (PDMP), cell adhesion molecules 
      (sCD40L and sP-selectin), chemokines [monocyte chemoattractant protein-1 (MCP-1) 
      and regulated on activation normally T-cell expressed and secreted] and 
      adiponectin were measured at the baseline and after 6 months of treatment in both 
      the groups. In addition, we carried out a basic study to investigate the 
      MCP-1-dependent induction of tissue factor expression on a histiocytic cell line 
      (U937 cells). The plasma levels of PDMP, sCD40L, sP-selectin, regulated on 
      activation normally T-cell expressed and secreted and MCP-1 were higher, whereas 
      those of adiponectin were lower, in the hyperlipidemic patients than in the 
      normolipidemic controls. Plasma PDMP and sCD40L were positively correlated, 
      whereas plasma adiponectin was negatively correlated, with the plasma levels of 
      MCP-1. No significant differences in the plasma levels of PDMP, sCD40L, 
      sP-selectin, regulated on activation normally T-cell expressed and secreted and 
      MCP-1 measured before and after treatment were observed in either the simvastatin 
      or pitavastatin group. A significant increase of the plasma adiponectin levels 
      was observed after 6 months of treatment with pitavastatin but not after an equal 
      duration of treatment with simvastatin. When pitavastatin-treated patients were 
      divided into two groups according to the adiponectin response to pitavastatin 
      treatment, significant decreases of the plasma MCP-1, PDMP and sCD40L levels were 
      observed after pitavastatin treatment in the responder group. In the 
      aforementioned basic study, MCP-1 by itself did not induce the expression of 
      tissue factor on the U937 cells. However, the recombinant sCD40L-induced 
      expression of tissue factor on U937 was enhanced by the addition of MCP-1. These 
      findings suggest that PDMP, sCD40L and MCP-1 may participate in the development 
      of atherothrombosis in patients with hyperlipidemia and that pitavastatin may 
      exert an adiponectin-dependent antiatherothrombotic effect in hyperlipidemic 
      patients.
FAU - Nomura, Shosaku
AU  - Nomura S
AD  - Division of Hematology, Kishiwada City Hospital, Japan. shosaku-n@mbp.ocn.ne.jp
FAU - Shouzu, Akira
AU  - Shouzu A
FAU - Omoto, Seitarou
AU  - Omoto S
FAU - Inami, Norihito
AU  - Inami N
FAU - Shimazu, Takayuki
AU  - Shimazu T
FAU - Satoh, Daisuke
AU  - Satoh D
FAU - Kajiura, Takayuki
AU  - Kajiura T
FAU - Yamada, Kohichi
AU  - Yamada K
FAU - Urase, Fumiaki
AU  - Urase F
FAU - Maeda, Yasuhiro
AU  - Maeda Y
FAU - Iwasaka, Toshiji
AU  - Iwasaka T
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Blood Coagul Fibrinolysis
JT  - Blood coagulation & fibrinolysis : an international journal in haemostasis and 
      thrombosis
JID - 9102551
RN  - 0 (ADIPOQ protein, human)
RN  - 0 (Adiponectin)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (P-Selectin)
RN  - 0 (Quinolines)
RN  - 147205-72-9 (CD40 Ligand)
RN  - 9035-58-9 (Thromboplastin)
RN  - M5681Q5F9P (pitavastatin)
SB  - IM
MH  - Adiponectin/blood
MH  - Adult
MH  - Aged
MH  - Atherosclerosis/etiology/prevention & control
MH  - CD40 Ligand/blood
MH  - Cell-Derived Microparticles
MH  - Chemokine CCL2/*blood
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology/therapeutic use
MH  - Hyperlipidemias/blood/complications/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - P-Selectin/blood
MH  - Quinolines/*pharmacology/therapeutic use
MH  - T-Lymphocytes/drug effects/metabolism
MH  - Thrombophilia/etiology/prevention & control
MH  - Thromboplastin/biosynthesis
MH  - U937 Cells/drug effects
EDAT- 2009/06/16 09:00
MHDA- 2009/12/23 06:00
CRDT- 2009/06/16 09:00
PHST- 2009/06/16 09:00 [entrez]
PHST- 2009/06/16 09:00 [pubmed]
PHST- 2009/12/23 06:00 [medline]
AID - 10.1097/MBC.0b013e32832e0618 [doi]
PST - ppublish
SO  - Blood Coagul Fibrinolysis. 2009 Sep;20(6):440-7. doi: 
      10.1097/MBC.0b013e32832e0618.